Early neurological deterioration (END) is associated with a poor prognosis in patients with high‑risk non‑disabling ischemic cerebrovascular events (HR‑NICE). Clopidogrel-based dual antiplatelet therapy is substantially limited by the CYP2C19 gene polymorphism. This study aimed to investigate whether low‑dose ticagrelor (60 mg twice daily) plus aspirin dual antiplatelet therapy was superior to clopidogrel plus aspirin for preventing END within 7 days in HR-NICE patients, without increasing the bleeding risk. This was a multicenter, prospective, randomized, open-label, blinded-endpoint clinical trial conducted in China. Patients with HR‑NICE within 24 h of onset were enrolled. They were randomly assigned to receive low-dose ticagrelor (60 mg twice daily) plus aspirin (TA group) or clopidogrel plus aspirin (LA group) in a 1:1 ratio. The primary outcome was END within 7 days, defined as a ≥ 2-point National Institutes of Health Stroke Scale (NIHSS) score increase or NIHSS motor score ≥ 1-point compared with baseline. Secondary outcomes included an excellent functional outcome (modified Rankin Scale [mRS] score 0–1) at 90 days and major ischemic vascular events within 90 days. Safety outcomes included any bleeding events. Intention‑to‑treat analysis was performed in this trial. A total of 334 patients were randomized to the TA group (n=167) or the LA group (n=167). The incidence of END within 7 days was 10.8 http://www.chictr.org.cn . Identifier: ChiCTR2300068509. Date of registration: February 21, 2023.

ZDHHC8 (ZDHHC Palmitoyltransferase 8) is a key gene that regulates cancer cell proliferation and is a potential therapeutic target. It is linked to a poor prognosis and is markedly overexpressed in many malignancies, including chronic lymphocytic leukemia (CLL). However, its pathogenic mechanism in CLL remains unclear. To identify important genes, RNA sequencing data from the Gene Expression Omnibus (GEO) collection were analyzed for differential expression. Subsequently, machine learning methods were employed to prioritize the core candidate genes. Additionally, important metabolic pathways were identified using Gene Set Enrichment Analysis (GSEA). Furthermore, protein-protein interaction (PPI) studies were used to identify the downstream targets of the core genes. Mendelian randomization (MR) analysis was used to investigate the regulatory mechanisms of CLL’s core genes. ZDHHC8 expression was markedly elevated in CLL patients and was linked to a poor prognosis. CAV1 is a key downstream target of ZDHHC8 in regulating CLL proliferation and anti-apoptosis. Mechanistically, ZDHHC8 expression grouping-based GSEA showed a notable enrichment of cellular lipid metabolism pathways, indicating that this is a major mechanism by which ZDHHC8 facilitates the development of CLL. MR analysis revealed substantial evidence of a positive causal connection between increased CAV1 expression and increased lipid metabolism. Further research has revealed that ZDHHC8 palmitoylates CAV1, activating cellular lipid metabolism to supply energy to cancer cells and driving the proliferation of malignant CLL.This work investigates the method by which ZDHHC8 regulates lipid metabolism via palmitoylation, specifically the involvement of the ZDHHC8/CAV1/lipid metabolism axis in CLL malignant proliferation, which could be a viable therapeutic target for CLL.

INTRODUCTION:This study was aimed to identify the discrepancies in treatment goals and concerns regarding disease management between patients with myeloproliferative neoplasms (MPNs) and hematologists. METHODS:A study was conducted among patients with MPNs, including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), and hematologists in China. RESULTS:Data from 1,645 respondents with ET, PV, and MF and 715 hematologist respondents were analyzed. Cure of disease and healthy blood counts as treatment goals were reported more by almost half of the respondents with MPNs than by hematologists. However, prevention of thrombotic events, delayed transformation of disease, improvement of symptoms and better quality of life, and reduction in spleen size were less reported by respondents with MPNs than by hematologists. In multivariate analyses, education, comorbidities, symptom burden, disease duration, and annual out-of-pocket expenses for treatment were significantly associated with the treatment goals of respondents with MPNs. However, female physicians and senior professors paid more attention to these goals. Regarding concerns on MPN-related issues, more respondents with MPNs paid more attention to disease knowledge and restrictions in daily life compared to hematologists, whereas the majority of physicians attached importance to medication-related issues. CONCLUSION:The perceptions of patients with MPNs and hematologists differed in terms of treatment goals and concerns of management of MPNs. Sociodemographic and clinical variables were associated with the respondents' perspectives on MPNs. Therefore, sufficient patient-physician communication is suggested to improve treatment satisfaction and compliance.

Rheumatoid arthritis (RA) is a worldwide public health problem. Intervention and prevention before the onset of rheumatic diseases is a new direction in current research. The aim of this study was to evaluate the potential and feasibility of traditional Chinese medicine (TCM) in the prevention of RA. This was a single-armed prospective clinical trial. All participants were recruited from a single center in Guangdong, China. Adults who tested positive for anti-cyclic citrullinated peptide antibody (anti-CCP) and/or rheumatoid factor (RF), had no synovitis and had never been treated with disease-modifying anti-rheumatic drugs (DMARDs), were enrolled to take the Huayu-Qiangshen-Tongbi-Optimized (HQTO) decoction orally twice daily, 200 mL each time for 24 weeks. Primary outcome was the proportion of patients who met 2010 ACR(American College of Rheumatology)/EULAR(European League Against Rheumatism) classification criteria of RA during observation. Secondary outcomes included levels of anti-CCP, RF, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), assessment of signs and symptoms, and radiographic progression by magnetic resonance imaging (MRI). 19 individuals were enrolled in the study, 4 of whom withdrew because of the epidemic of COVID-19. During the observation period, 3 individuals (20%) developed RA and they had longer morning stiffness at baseline (P=0.009) when compared with those who did not develop RA. After 24 weeks of intervention, there were improvements in 28-swollen joint count (SJC28) (P=0.046), Visual Analog Scale (VAS) (P=0.019), Patient's Global Assessment (PtGA) (P=0.019) and Physician's Global Assessment (PGA) (P=0.031), but no statistical significance was observed in the levels of anti-CCP, RF, ESR, CRP, morning stiffness, 28-tender joint count (TJC28), Health Assessment Questionnaire (HAQ) and magnetic resonance imaging (MRI) analysis (P>0.05). The HQTO formula is safe and could improve joint symptoms and signs in these at-risk individuals, but it remains to be investigated in futher study to see if it might potentially reduce the risk of developing RA. Besides, for individuals at high risk to develop RA, morning stiffness and synovial enhancement in MRI might be predictive factors and warning signs. Chinese Clinical Trial Registry, ChiCTR1900025482. Registered 28 August 2019, http://www.chictr.org.cn/showprojen.aspx?proj=41629

Objective: To evaluate the difference in body surface temperature characteristics between patients with malignant lymphoma and healthy people by infrared thermography, and to find the independent risk factors for malignant lymphoma in temperature characteristics. Methods: The infrared heat maps of 40 patients with malignant lymphoma and 40 healthy people who were admitted to Dongzhimen Hospital from December 2022 to December 2023 were collected, and the temperature characteristics of the target area were measured and analyzed. Results: The average temperature of hands and feet in the malignant lymphoma group was higher than that in the normal control group. The average temperature of the abdomen, spine and back of the control group was lower than that of the normal control group (P < 0.05). The homogeneity of the neck and abdomen was worse than that of the normal control group (P < 0.05). The symmetry of the anterior, neck and clavicle region was worse than that of the normal control group (P < 0.05). Lower abdominal homogeneity and neck symmetry were independent risk factors for the diagnosis of malignant lymphoma (P<0.05). Conclusion: Infrared thermal imaging is beneficial to the screening of malignant lymphoma and the evaluation of therapeutic effect.

Objective:To evaluate the clinical efficacy and safety of Xihuang Capsules combined with chemotherapy in the treatment of malignant tumors.Methods:CNKI,CCD,CSPD,CBM,PubMed, Web of Science, and Medline databases were searched comprehensively for randomized controlled trials（RCTs） of Xihuang Capsules combined with chemotherapy for malignant tumors from database inception to June 2020 according to the preset inclusion criteria, followed by Meta-analysis.Results:A total of 395 research articles were initially retrieved, and finally 16 RCTs were included, involving 1 288 samples.The meta-analysis found that Xihuang Capsules combined with chemotherapy could improve the total response rate（RR） and disease control rate（DCR） of gastrointestinal cancers（esophageal cancer, gastric cancer, and colon cancer）,lung cancer, and breast cancer, but the clinical efficacy of cervical cancer was not improved.Due to the limitation of the number of studies, their usage in cervical cancer conclusions should be cautious.In addition, this study also found that Xihuang Capsules combined with chemotherapy could improve the KPS score and immune function indicators such as CD3 + ,CD4 + ,and CD4 + /CD8 + ,and reduce the incidence of decrease in blood platelets and Ⅲ～Ⅳ° white blood cells and liver and kidney damage.However, there was no improvement in the incidence of gastrointestinal reactions, reduction in hemoglobin, and Ⅰ～Ⅱ° white blood cells.Conclusion:Xihuang Capsules combined with chemotherapy can improve the clinical efficacy of patients with malignant tumors and reduce the incidence of liver and kidney damage and thrombocytopenia.The conclusion of this study needs more high-quality RCTs for verification.

Objectives: To investigate the clinical and genetic features of young Chinese patients with myeloproliferative neoplasms (MPN). Methods: In this cross-sectional study, anonymous questionnaires were distributed to patients with MPN patients nationwide. The respondents were divided into 3 groups based on their age at diagnosis: young (≤40 years) , middle-aged (41-60 years) , and elderly (>60 years) . We compared the clinical and genetic characteristics of three groups of MPN patients. Results: 1727 assessable questionnaires were collected. There were 453 (26.2%) young respondents with MPNs, including 274 with essential thrombocythemia (ET) , 80 with polycythemia vera (PV) , and 99 with myelofibrosis. Among the young group, 178 (39.3%) were male, and the median age was 31 (18-40) years. In comparison to middle-aged and elderly respondents, young respondents with MPN were more likely to present with a higher proportion of unmarried status (all P<0.001) , a higher education level (all P<0.001) , less comorbidity (ies) , fewer medications (all P<0.001) , and low-risk stratification (all P<0.001) . Younger respondents experienced headache (ET, P<0.001; PV, P=0.007; MF, P=0.001) at diagnosis, had splenomegaly at diagnosis (PV, P<0.001) , and survey (ET, P=0.052; PV, P=0.063) . Younger respondents had fewer thrombotic events at diagnosis (ET, P<0.001; PV, P=0.011) and during the survey (ET, P<0.001; PV, P=0.003) . JAK2 mutations were found in fewer young people (ET, P<0.001; PV, P<0.001; MF, P=0.013) ; however, CALR mutations were found in more young people (ET, P<0.001; MF, P=0.015) . Furthermore, mutations in non-driver genes (ET, P=0.042; PV, P=0.043; MF, P=0.004) and high-molecular risk mutations (ET, P=0.024; PV, P=0.023; MF, P=0.001) were found in fewer young respondents. Conclusion: Compared with middle-aged and elderly patients, young patients with MPN had unique clinical and genetic characteristics.

Objective:To explore the medication rules and mechanism of traditional Chinese medicine（TCM） in treating patients with advanced gastric cancer through data mining technology combined with network pharmacology and gene chip technology. Methods:Medical records of 135 patients with advanced gastric cancer who benefited from TCM treatment were collected, core drug combinations were obtained by data mining technology, common targets of drugs and diseases were obtained by network pharmacology combined with gene chip technology, and relevant mechanisms of action were explored. The expression of key targets in gastric cancer and their relationship with the survival of gastric cancer were explored through Oncomine and Kaplan-Meier Plotter databases. Results:Among the 135 patients who benefited from the treatment of advanced gastric cancer,there were 81 males and 54 females, with an average age of 59.33 years. The drug frequency from high to low mainly included Huangqi（Astragalus）, Dangshen（Codonopsis）, Banxia（Pinellia）, Chenpi（Tangerine Peel）, Fuling（Poria）, and so on. The four Qi were mainly warm, flat and cold, and the five flavors were mainly sweet, bitter and pungent. The main meridian was the spleen meridian. "Huangqi（Astragalus）-Dangshen（Codonopsis）-Banxia（Pinellia）-Chenpi（Tangerine Peel）-Fuling（Poria）" was the core drug combination of 135 prescriptions, which had 77 effective active ingredients. Taking the gastric cancer samples of GSE63089 and GSE118916 datasets in GEO database as the research object, a total of 520 differential genes of gastric cancer were obtained, of which58 drugs shared common targets with gastric cancer. NTRK1, TP53, MCM2, CUL3, and CDK2 were key targets.It was found that there were significant differences in the expression of NTRK1, TP53, and MCM2 in gastric cancer and normal tissues through the Oncomine database（P＜0.05）. Through the Kaplan Meier Plotter database,it was found that the overall survival（OS） and first progression time（FP） in the high expression group of NTRK1, TP53, and MCM2 were lower than those in the low expression group, with statistically significant differences（P＜0.05）. Conclusions:The study found that the TCM prescription of advanced gastric cancer is mainly to strengthen the spleen and replenish Qi, regulate Qi and remove phlegm. The core prescription is "Huangqi（Astragalus）-Dangshen（Codonopsis）-Banxia（Pinellia）-Chenpi（Tangerine Peel）-Fuling（Poria）". It regulates key targets such as NTRK1, TP53, MCM2, CUL3, and CDK2 through active ingredients such as quercetin, isorhamnetin,kaempferol and luteolin to participate in the regulation of tumor cell cycle, inflammatory response and other processes,and plays an anti-gastric cancer role by regulating cell cycle and p53 signal pathway. NTRK1, TP53, and MCM2 are highly expressed in gastric cancer tissues. The higher the expression levels of the three, the shorter the survival time of gastric cancer patients.

李冬云教授认为,多发性骨髓瘤便秘的基本病机为正虚为本,毒瘀为标,虚实夹杂.治疗上注重整体,倡导中西医结合治疗.主张分期辨证论治,善用枳术丸临证加减,治疗前期应解毒祛瘀,顾护胃气;治疗中期应健运脾胃,以补开塞;治疗后期应滋补肝肾,增液行舟.巧用中医外治,控制并发症.同时注重日常调摄,调护情志.审证求机,组方用药,取得了较好的疗效.附验案1 则,加以佐证.

Introduction: Genetic landscape, disease characteristics, and clinical outcomes of young adults with myeloproliferative neoplasms (MPNs) were reported. However, data on patient-reported outcomes (PROs) in young adults with MPNs were rare. Methods: We conducted a multicenter, cross-sectional study to compare the PROs in respondents with thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) by age at survey, including the young group (18–40 years), middle-aged group (41–60 years), and elderly group (>60 years). Results: Of the 1,664 respondents with MPNs, 349 (21.0%) were young including 244 (69.9%) with ET, 34 (9.7%) with PV, and 71 (20.3%) with MF. In multivariate analyses, the young groups with ET and MF were associated with the lowest MPN-10 scores among the 3 age groups; those with MF, highest proportion of reporting negative impact of disease and therapy on their daily life and work. The young groups with MPNs had the highest physical component summary scores but the lowest mental component summary scores in those with ET. The young groups with MPNs were most concerned about fertility; those with ET, treatment-related adverse events and long-term efficacy of treatment. Conclusions: We concluded that young adults with MPNs have different PROs compared with middle-aged and elderly patients.

介绍李冬云教授基于祛瘀生新法治疗恶性血液病化疗后骨髓抑制的经验.李冬云认为,恶性血液病化疗后骨髓抑制的基本病机为正虚为本,毒瘀为标,瘀血为病机的主要环节,因虚致瘀、因郁致瘀、毒瘀并存、脾肾亏虚,造成骨髓抑制,病情缠绵,多发变证.李冬云临证以祛瘀生新为治疗大法,通过解毒祛瘀、活血化瘀以祛除体内陈腐瘀血,通过疏肝理气、健脾益肾以促进新血的生成,同时注重患者情志的疏导和饮食的调护,使瘀去气血平,瘀去新血生.

痰瘀相关理论首见于《内经》,基于中医学"津血同源"理论而产生.恶性淋巴瘤(ML)中医学称痰核、恶核、积聚等,临床以无痛性、进行性淋巴组织增生,尤以浅表淋巴结肿大为特点,病程较长,易复发.痰瘀是ML核心病机,应以痰瘀同治为原则,其中包含补气扶正、理气疏肝、脾肾同补、清热解毒4个方面,标本同治,气血同调.

目的 通过网络药理学方法研究夏枯草-半夏治疗弥漫大B细胞淋巴瘤(Diffuse large B-cell lym-phoma,DLBCL)的潜在分子机制.方法 首先利用中药系统药理学数据库和分析平台(Traditional Chinese medi-cine system platform,TCMSP)筛选夏枯草-半夏的活性成分及其对应的靶基因.其次,通过GeneCards、OMIM、TTD、DrugBank等数据库搜索DLBCL的疾病靶点,取交集后得到夏枯草-半夏治疗DLBCL的共同靶标基因,将共同靶标基因导入Cytoscape构建"夏枯草-半夏活性成分-DLBCL靶标基因"关系网络图.再通过PPI网络分析,筛选核心靶基因,进行基因本体论和京都基因与基因组百科全书通路分析.结果 夏枯草-半夏治疗DLBCL的主要活性成分有13种,包括槲皮素、β-谷甾醇、豆甾醇等;其作用的核心靶点包括AKT1、JUN、TP53、MAPK1、TNF等;其主要通过调节PI3K-Akt信号通路、TNF信号通路等信号通路发挥治疗DLBCL的作用.结论 夏枯草-半夏可通过多靶标、多途径发挥辅助治疗DLBCL的作用.

"玄府"一词源于《黄帝内经》,经历朝历代医家的发挥,至今已形成较完善的玄府理论.从玄府理论新视角出发,可将类风湿关节炎的病机归纳为玄府开阖失常.蠲痹汤为临床上治疗类风湿关节炎的经典方剂,本文以此方为代表,浅谈临床实践中恢复玄府开阖功能对类风湿关节炎治疗的重要性,以期为类风湿关节炎的辨治提供新思路.

Objectives: To explore health-related quality of life (HRQoL) and identify its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) . Methods: In this cross-sectional study, anonymous questionnaires were distributed to adult patients with MPNs to assess symptom burden measured by MPN-10 and HRQoL measured by Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) . Results: The data from 1405 respondents with MPNs, including 645 (45.9%) with essential thrombocythemia (ET) , 297 (21.1%) with polycythemia vera (PV) , and 463 (33.0%) with myelofibrosis (MF) , were analyzed. 646 (46.0%) respondents were male. The median age was 56 (range, 18-99) years. The mean MPN-10 scores were 13.0±12.7, 15.0±14.7, and 21.0±16.6 (P<0.001) , and the physical component summary (PCS) and mental component summary (MCS) scores were 48.0±8.5, 47.0±9.0, and 42.0±10.0 (P<0.001) and 51.0±11.0, 50.0±10.8, and 49.0±11.1 (P=0.002) for respondents with ET, PV, and MF, respectively. Respondents with MF reported the lowest score of physical functioning, role functioning, emotional functioning, cognitive functioning, social function, and global health status (all P<0.01) and the highest score of fatigue, pain, dyspnea, appetite loss, diarrhea, and financial problems (all P<0.05) in EORTC QLQ-C30. Multivariate analyses revealed that higher MPN-10 scores were significantly associated with lower PCS (-0.220 to -0.277, P<0.001) and MCS (-0.244 to -0.329, P<0.001) scores; increasing age (-1.923 to -4.869; all P<0.05) , lower PCS score. Additionally, comorbidity (ies) , symptom at diagnosis, splenomegaly, anemia, unknown driver gene, and higher annual out-of-pocket cost were significantly associated with lower PCS and/or MCS scores. However, age ≥ 60 years, urban household registration, concomitant medication, and receiving ruxolitinib therapy in respondents with MF were associated with higher MCS scores. Weak correlations were found between MPN-10 score (except the subscale of appetite loss and constipation) and EORTC QLQ-C30 score in majority of subscales in respondents with ET (|r| = 0.193-0.457, all P<0.001) , PV (|r| = 0.192-0.529, all P<0.01) , and MF (|r| = 0.180-0.488, all P<0.001) , respectively. Conclusions: HRQoL in patients with MPN was significantly reduced, especially in patients with MF. Sociodemographic and clinical variables were significantly associated with the HRQoL in patients with MPNs.

We explored variables associated with patient-reported outcomes (PROs) including symptom burden, impact on daily life and work, obstacles during therapy, satisfaction level with therapy, and health-related quality of life in 1500 respondents with myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF) in a multicenter, cross-sectional study across China, a representative of the developing countries. In multivariate analyses, urban household registration and higher education level were significantly-associated with no symptoms at diagnosis in respondents with ET or MF. CALR mutation was significantly-associated with lower MPN-10 scores in respondents with MF. Higher MPN-10 scores were significantly-associated with negative impact on daily life and work as well as lower satisfaction level in respondents with ET, PV and MF. Receiving ruxolitinib was significantly-associated with high satisfaction and satisfaction in respondents with MF. In addition, other demographics and clinical variables were also impacting PROs.

"正邪失衡""阴阳失调"是恶性肿瘤发生发展的根本原因,基于调平理论,及时纠正机体失衡状态,在机体出现病理产物之前建立新动态平衡,让机体自我修复能力在"调平"措施的帮助下,恢复抵御邪气的能力.基于调平理论确立治则治法可用于实体恶性肿瘤和血液系统恶性肿瘤治疗中,解决恶性肿瘤治疗难题,提高生命质量,延长生存期.

生血宁片来源于中药蚕砂提取物,主要成分为铁叶绿酸钠和叶绿素衍生物,能够有效补充合成血红蛋白所需要的铁元素,直接参与人体血红蛋白的合成,其治疗癌性贫血的作用机制可能与抑制白细胞介素-6、肿瘤坏死因子-α、C-反应蛋白等炎性介质的产生,抑制铁调素的高表达,调节铁代谢紊乱及抑制氧化应激反应等有关.对生血宁片治疗癌性贫血的研究进行概述,临床和实验研究证实了生血宁片治疗癌性贫血的有效性和科学性,为中医药防治癌性贫血提供了新思路.

目的:系统评价国内抗幽门螺旋杆菌治疗在儿童原发免疫性血小板减少症的疗效.方法:计算机检索VIP、CNKI、Wanfang、SinoMed、Medline、Cochrane Library、PubMed,检索时间为各数据库建库至2019年4月16日,按照预先制定的遴选标准筛选出抗Hp(幽门螺旋杆菌)治疗儿童ITP(原发免疫性血小板减少症)的随机对照试验.用Rev Man5.3软件进行Meta 分析,用TSA0.9.5.10Beta软件进行试验序贯分析.结果:共检索出268篇文献,最终纳入14个研究,总样本量为833例.Meta分析结果显示:常规治疗联合抗Hp治疗在临床疗效、复发率、血小板计数、血液流变学指标和Hp阳性率等方面优于单纯常规治疗组,但在不良反应方面,由于文献数量较少,暂不能得出结论.试验序贯分析显示:在临床总有效率方面,累积Z值穿过了传统界值和TSA界值,提前得到肯定结论;在半年内复发率方面,累积Z值虽然穿过了传统界值,但并未与TSA界值相交,提示Meta分析结果可能为假阳性.结论:本研究结果提示常规治疗联合抗Hp治疗能增加儿童ITP的临床疗效,降低复发率.但因纳入研究质量等问题,本研究结论还有待更多关于抗Hp治疗的儿童ITP患者的高质量、随机双盲的随机对照试验.

恶性血液病是指各型急慢性白血病、淋巴瘤、骨髓增生异常综合征、骨髓增殖性肿瘤、多发性骨髓瘤等血液系统恶性肿瘤.化疗是大多数恶性血液病的常规治疗手段,但化疗药物在杀伤肿瘤细胞的同时也会杀伤人体的正常细胞,引起一系列不良反应的发生.胃气是中医基础理论的一个重要概念,脾胃为"后天之本",气血生化之源,气机升降之枢纽,且与他脏有密切联系,而胃气是脾胃功能的重要体现,探讨"有胃气则生"理论在临床中的应用有重要意义.脾胃亏虚是恶性血液病化疗患者的重要病因,是肿瘤发病的重要因素,化疗导致恶性血液病患者脾胃虚弱加重.调理脾胃、顾护胃气在恶性血液病化疗中具有重要作用.化疗前期,以理气祛邪为主,兼以顾护胃气;化疗期,扶正祛邪,调理脾胃;化疗后期,扶正培本,恢复胃气.中西医结合疗效更佳.临床应结合辨证遣药组方,药物宜纯、宜平,分量宜轻,避免使用大辛大热、大苦大寒、大补大泻等伤脾败胃之品.